Home \ Pharmacovigilance

Pharmacon supervision Russia

LLC NPK Pharmasoft performs constant monitoring of the safety of our products. The collection of security information gives the company the opportunity to receive and provide patients and doctors with the most complete and reliable information about the drug, which in turn helps doctors to better control the treatment of patients. Following the ethical principles and requirements of the legislation of the Russian Federation and other countries, we collect information on security, process it, evaluate and bring to the attention of regulatory bodies and doctors.

If you became aware of the undesirable phenomena that arose in the process of using drugs LLC NPK Pharmasoft, and/or about claims to their effectiveness and quality, please report this:

at the address: 109544, Moscow,
Entuziastov Boulevard, 2

by email:
pv@pharmasoft.ru

Or call the phone:
+7 (495) 626-47-55

This information is very important to us! Your assistance helps us improve the safety and efficacy of our products and protect the rights, well-being, and safety of patients.
The sender of this message confirms that the information provided is complete, accurate, and reliable and does not violate current legislation or the legal rights and interests of third parties. The information received will not be publicly disseminated. It may be submitted to authorized regulatory authorities. In accordance with the provisions of the Good Pharmacovigilance Practice Rules, approved by Decision No. 87 of the Council of the Eurasian Economic Commission dated November 3, 2016, the information provided is subject to processing, systematization, anonymization, and storage for at least 10 years after the expiration of the state registration certificates.

    with an asterisk "*" are required.


    A member of the Pharmacovigilance Department at PHARMASOFT Research and Production Company LLC may contact the person submitting the message to clarify the information provided in the message. This consent is valid indefinitely and may be revoked by sending a written request to pv@pharmasoft.ru.

    Notification of an undesirable reaction or absence of the therapeutic effect of the drug

    Data of the reporting person



    Information about the patient


    The drug (PM) No. 1, which supposedly caused an unwanted reaction (hereinafter referred to as the text of the HP)

    Drug (PM) No. 2, which supposedly caused HP

    Drug (PM) No. 3, which supposedly caused HP

    Other drugs taken over the past 3 months, including drugs taken by the patient independently (by his own decision)

    Add the drug

    Description of Nr*:

    Select from the list*

    Exodus*

    The consequences of recovery

    Criteria for the seriousness of NR:

    Significant additional information:

    The data of clinical, laboratory, radiological studies and autopsy, including the determination of the concentration of drugs in the blood/tissues, if any are related to HP (please give dates). 

    Concomitant conditions. Medical history, suspected drug interactions:
    For congenital anomalies, list all other medications taken during pregnancy, as well as the date of the last menstrual period.
    Please attach additional pages if necessary.

    with an asterisk "*" are required.

    THE INFORMATION IS INTENDED FOR HEALTHCARE AND PHARMACEUTICAL PROFESSIONALS. THIS INFORMATION IS NOT INTENDED AS A SUBSTITUTE FOR MEDICAL ADVICE.

    Source of photos and images Shutterstock.com